ArticleNeuropsychiatric disease and treatment2016
Validation of the Chinese version of Brief Assessment of Cognition in Schizophrenia.
Article in Neuropsychiatric disease and treatment, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04998097 (Changes in Serum miRNA and BDNF Levels in Bipolar II Depression Treated by Theta-burst Stimulation), which is not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Changes in Serum miRNA and BDNF Levels in Bipolar II Depression Treated by Theta-burst Stimulation: A Randomized Sham-controlled Exploratory Study
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Exploring the Relationship between Cognitive Performance, Performance-Based Functioning, and Everyday Functioning in People with Schizophrenia: a Systematic Literature Review.Schizophrenia bulletin · 2026Pooled it
- Processing Speed Impairment in Schizophrenia: An Updated Systematic Review and Meta-Analysis.JAMA psychiatry · 2026Pooled it
- European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022Pooled it
- Does neurocognition predict personal recovery over time in psychotic disorder patients?Schizophrenia research. Cognition · 2026Article
- Cortical excitability mapping stratifies neurobiological subtypes of schizophrenia with genetic and molecular signatures.BMC medicine · 2026Article
- Altered resting-state prefrontal activity and network topology in adolescents with depression: an fNIRS study.Frontiers in psychiatry · 2026Article
- Efficacy of Baduanjin Versus Brisk Walking on Cognitive and Physical Functions in Schizophrenia: A Three-Arm Randomized Controlled Trial.Healthcare (Basel, Switzerland) · 2025Article
- Protein biomarkers for bipolar II disorder are correlated with affective cognitive performance.BMC psychiatry · 2025Article
- A cross-sectional study on the association between executive functions and social disabilities in people with a psychotic disorder.Schizophrenia research. Cognition · 2025Article
- Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities.Schizophrenia bulletin · 2025Review
- Development and Evaluation of a Cognitive Battery for People With Schizophrenia in Ethiopia.Schizophrenia bulletin · 2024Article
- Self-report versus performance based executive functioning in people with psychotic disorders.Schizophrenia research. Cognition · 2023Article
- Cross-Cultural Adaptation and Validation of the Serbian Version of the Brief Assessment of Cognition in Schizophrenia Scale.International journal of environmental research and public health · 2023Article
- The Relationship Between Level of Education, Cognitive Function and Medication Adherence in Patients with Schizophrenia.Neuropsychiatric disease and treatment · 2023Article
- A subtype of institutionalized patients with schizophrenia characterized by pronounced subcortical and cognitive deficits.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Validation of the Chinese Version of the Schizophrenia Cognition Rating Scale.Psychiatry investigation · 2022Article
- Linked brain connectivity patterns with psychopathological and cognitive phenotypes in drug-naïve first-episode schizophrenia.Psychoradiology · 2022Article
- Distinct neuroanatomic subtypes in antipsychotic-treated patients with schizophrenia classified by the predefined classification in a never-treated sample.Psychoradiology · 2021Article
- Cross-cultural adaptation and validation of the Arabic version of the BACS scale (the brief assessment of cognition in schizophrenia) among chronic schizophrenic inpatients.BMC psychiatry · 2021Article
- Prevalence and association of depression with uremia in dialysis population: a retrospective cohort analysis.Medicine · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveA test battery that measures cognitive function impairment in patients with schizophrenia, the Brief Assessment of Cognition in Schizophrenia (BACS), has been translated into various languages and validated. This study aimed to test the reliability and validity of the Chinese version of the BACS in a Chinese-speaking population.
methodsAll participants in this study (66 patients with schizophrenia [mean age: 41.2 years, 57.6% male] and 66 age- and sex-matched healthy controls) were from Taiwan and assessed using the BACS and the University of California, San Diego (UCSD) Performance-Based Skills Assessment, Brief Version (UPSA-B). Thirty-eight of the 66 patients with schizophrenia received a reassessment using the BACS.
resultsThe BACS had good test-retest reliability, and all BACS subtests had statistically insignificant practice effects. Principal components analysis demonstrated that a one-factor solution best fits our dataset (60.9% of the variance). In both patients and controls, the BACS composite scores were positively correlated with all BACS subscales (
conclusionThe Chinese version of the BACS exhibits satisfactory psychometric properties, including high test-retest reliability, high internal consistency, acceptable concurrent validity, and good discriminant validity. We suggest that the BACS is a reliable and practical tool for assessing cognitive function in patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.